Scott Schoenhaus
Stock Analyst at Keybanc
(2.15)
# 1,506
Out of 4,412 analysts
64
Total ratings
39.66%
Success rate
-4.44%
Average return
Main Sectors:
18 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCM R1 RCM | Downgrades: Sector Weight | n/a | $11.90 | - | 8 | Apr 10, 2024 | |
| HCAT Health Catalyst | Downgrades: Sector Weight | n/a | $6.03 | - | 4 | Apr 10, 2024 | |
| GDRX GoodRx Holdings | Upgrades: Overweight | $9 | $7.19 | +25.17% | 4 | Apr 10, 2024 | |
| CERT Certara | Upgrades: Overweight | $23 | $16.57 | +38.81% | 2 | Apr 10, 2024 | |
| HQY HealthEquity | Maintains: Overweight | $85 → $95 | $80.26 | +18.37% | 2 | Mar 22, 2024 | |
| VEEV Veeva Systems | Maintains: Overweight | $232 → $250 | $200.91 | +24.43% | 10 | Mar 5, 2024 | |
| RXRX Recursion Pharmaceuticals | Maintains: Overweight | $15 → $16 | $8.12 | +97.04% | 4 | Mar 4, 2024 | |
| ABSI Absci | Maintains: Overweight | $5 → $8 | $4.58 | +74.67% | 3 | Mar 4, 2024 | |
| SDGR Schrödinger | Maintains: Overweight | $38 → $33 | $23.97 | +37.67% | 2 | Feb 29, 2024 | |
| PHR Phreesia | Maintains: Overweight | $40 → $30 | $20.61 | +45.56% | 4 | Dec 7, 2023 | |
| ABCL AbCellera Biologics | Initiates: Overweight | $6 | $3.76 | +59.57% | 1 | Dec 5, 2023 | |
| PGNY Progyny | Maintains: Overweight | $50 → $45 | $32.04 | +40.45% | 4 | Nov 8, 2023 | |
| OMCL Omnicell | Downgrades: Sector Weight | n/a | $27.86 | - | 8 | Oct 11, 2023 | |
| ODD Oddity Tech | Initiates: Overweight | n/a | $32.19 | - | 1 | Aug 15, 2023 | |
| ALIT Alight | Maintains: Overweight | $15 → $12 | $9.11 | +31.72% | 3 | Aug 3, 2023 | |
| MDRX Veradigm | Initiates: Sector Weight | n/a | $7.96 | - | 1 | Sep 16, 2022 | |
| TDOC Teladoc Health | Initiates: Sector Weight | n/a | $13.01 | - | 2 | Sep 16, 2022 | |
| IQV IQVIA Holdings | Upgrades: Overweight | n/a | $234.88 | - | 1 | Apr 16, 2021 |
R1 RCM
Apr 10, 2024
Downgrades: Sector Weight
Price Target: n/a
Current: $11.90
Upside: -
Health Catalyst
Apr 10, 2024
Downgrades: Sector Weight
Price Target: n/a
Current: $6.03
Upside: -
GoodRx Holdings
Apr 10, 2024
Upgrades: Overweight
Price Target: $9
Current: $7.19
Upside: +25.17%
Certara
Apr 10, 2024
Upgrades: Overweight
Price Target: $23
Current: $16.57
Upside: +38.81%
HealthEquity
Mar 22, 2024
Maintains: Overweight
Price Target: $85 → $95
Current: $80.26
Upside: +18.37%
Veeva Systems
Mar 5, 2024
Maintains: Overweight
Price Target: $232 → $250
Current: $200.91
Upside: +24.43%
Recursion Pharmaceuticals
Mar 4, 2024
Maintains: Overweight
Price Target: $15 → $16
Current: $8.12
Upside: +97.04%
Absci
Mar 4, 2024
Maintains: Overweight
Price Target: $5 → $8
Current: $4.58
Upside: +74.67%
Schrödinger
Feb 29, 2024
Maintains: Overweight
Price Target: $38 → $33
Current: $23.97
Upside: +37.67%
Phreesia
Dec 7, 2023
Maintains: Overweight
Price Target: $40 → $30
Current: $20.61
Upside: +45.56%
AbCellera Biologics
Dec 5, 2023
Initiates: Overweight
Price Target: $6
Current: $3.76
Upside: +59.57%
Progyny
Nov 8, 2023
Maintains: Overweight
Price Target: $50 → $45
Current: $32.04
Upside: +40.45%
Omnicell
Oct 11, 2023
Downgrades: Sector Weight
Price Target: n/a
Current: $27.86
Upside: -
Oddity Tech
Aug 15, 2023
Initiates: Overweight
Price Target: n/a
Current: $32.19
Upside: -
Alight
Aug 3, 2023
Maintains: Overweight
Price Target: $15 → $12
Current: $9.11
Upside: +31.72%
Veradigm
Sep 16, 2022
Initiates: Sector Weight
Price Target: n/a
Current: $7.96
Upside: -
Teladoc Health
Sep 16, 2022
Initiates: Sector Weight
Price Target: n/a
Current: $13.01
Upside: -
IQVIA Holdings
Apr 16, 2021
Upgrades: Overweight
Price Target: n/a
Current: $234.88
Upside: -